Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultibro Breezhaler vs Nebulized Ipratropium/Salbutamol in COPD
NCT02576626Phase 4Completed
- Start
- Dec 2015
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of indacaterol and glycopyrronium in chronic obstructive pulmonary disease (COPD) (2 arms). Primary endpoint: Area under the curve of FEV1 from 0 to 6 hours. Started Dec 2015; status: completed.
02
Drugs
indacaterolglycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02576626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02576626.